BioPharmSignal logoBioPharmSignal

Biotech News

Personalis Reports First Quarter Results and Recent Highlights

Personalis (PSNL)PersonalisEarnings

Clinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1 M edicare coverage secured for lung cancer surveillance, providing a clear path to monetize rapidly growing clinical test volumes FREMONT, Calif. --(BUSINESS WIRE)--May 7, 2026-- Personalis, Inc.

Related news

PSNLPersonalis2026-08-04 20:01 EST

Personalis Reports Second Quarter Results and Recent Highlights

LEGNLegend Biotech Corporation2026-08-11 11:00 EST

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

View all latest news

Personalis

Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track...

Recent company news

PSNLPersonalis2026-08-04 20:01 EST

Personalis Reports Second Quarter Results and Recent Highlights

PSNLPersonalis2026-07-20 12:30 EST

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

PSNLPersonalis2026-07-14 10:00 EST

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

PSNLPersonalis2026-06-09 10:00 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-02 10:00 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Stock data

Close
18.38 USD
Market cap
1.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States